MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announced that Laurent Nguyen, Chief Executive Officer, is scheduled to present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016 at The Lotte New York Palace Hotel in New York City.
Dr. Nguyen will provide an overview of the company’s upcoming clinical and operational plans during a live presentation. Details of the presentation are as follows:
Date: Monday, September 12, 2016
Time: 11:15 AM EST
Room:
Louis (4th Floor)
Investors attending the conference who would like to schedule a one-on-one meeting with Sensorion’s management may do so by contacting their Rodman & Renshaw representatives, or Chris Nardo at The Ruth Group at cnardo@theruthgroup.com.
The presentation will also be webcast live. To access the webcast, please visit the Company’s website at www.sensorion.com. The webcast replay will remain available for 90 days following the live presentation.
About Sensorion
Spun off from Inserm (the French institute of health and medical research) in 2009, Sensorion is a biotech company that specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The Company has substantial pharmaceutical R&D experience and a comprehensive technological platform for developing easy-to-take (notably orally) first-in-class drug candidates for treating hearing loss and the symptoms of vertigo or tinnitus, for preventing complications associated with progressive lesions in the inner ear and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion receives financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.
For more information: www.sensorion-pharma.com
Name: SENSORION
ISIN code: FR0012596468
Ticker: ALSEN
